117 Results

European Commission approves Zirabev (bevacizumab biosimilar)to treat the same indications as the originator product. Avastin. - Pfizer

 Added 27 days ago

Pfizer Inc. announced the European Commission (EC) has approved Zirabev for the treatment of metastatic carcinoma of the colon or...

Updated results from Phase III BEACON CRC trial evaluating Braftovi + Mektovi + Erbitux for BRAFV600E-mutant colorectal cancer.- Array Biopharma

 Added 2 months ago

Array Biopharma announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase...

Unravelling the microbiome – health through happy communities

 Added 4 months ago

Unravelling the microbiome – health through happy communities

The human body is host to trillions of microbial organisms which live on skin, for instance, on the surface of lungs and on the surface of the gut.

Chinese regulatory approval for Elunate to treat colorectal cancer.- Hutchison China MediTech .

 Added 6 months ago

Hutchison China MediTech Limited (“Chi-Med”) announces that fruquintinib capsules have been granted approval for drug registration by the National Medical...

Exact Sciences and Pfizer enter Into U.S. promotion agreement For Cologuard to diagnose colorectal cancer.

 Added 6 months ago

Exact Sciences Corp. and Pfizer Inc. announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive...

Updated results from BEACON CRC trial of Braftovi + Mektovi + cetuximab for patients with BRAFV600E-mutant metastatic colorectal cancer.-Array Biopharma.

 Added 7 months ago

As presented at the ESMO 20th World Congress on Gastrointestinal Cancer in June 2018 , the results from the safety...

Phase III MORA trial of Plenvu in bowel preparation published in Endoscopy.- Norgine.

 Added 8 months ago

Norgine announced that results from the Plenvu (polyethylene glycol based bowel preparation) Phase III MORA trial were published in ENDOSCOPY,...

FDA provides accelerated approval for Yervoy + Opdivo combination to treat microsatellite instability high or mismatch repair deficient metastatic colorectal cancer.

 Added 8 months ago

Bristol-Myers Squibb Company announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval...

Phase III BEACON CRC trial positive for Braftovi + Mektovi and cetuximab combination in patients with BRAFV600E-mutant metastatic colorectal cancer.- Array BioPharma + Pierre Fabre

 Added 8 months ago

Array BioPharma Inc.has announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase III BEACON...

Eli Lilly to acquire AurKa Pharma and AK 01, an Aurora kinase A inhibitor, in early trials for solid tumours.

 Added 10 months ago

Eli Lilly and Company has announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life...

Load more